Physician profile
Eric R Levine
NPI 1528038734
$2,486.92
in general payments reported to CMS, 2019-2025
22 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.64 · 2020: $37.78 · 2023: $231 · 2024: $936 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $405.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $323.36 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.42 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $182.23 | 2020-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $177.87 | 2023-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $148.14 | 2024 | Arcalyst |
| Amgen INC. | $147.37 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $120.26 | 2024-2025 | Opsumit, Opsynvi |
| Novo Nordisk INC | $119.55 | 2024-2025 | Wegovy, Ozempic |
| Bridgebio Pharma, INC. | $91.95 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $79.57 | 2024-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $75.00 | 2025 | Onpattro, Amvuttra |
| Lexicon Pharmaceuticals, INC. | $67.02 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.79 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.15 | 2024-2025 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.47 | 2023-2024 | Xarelto |
| Abbott Laboratories | $49.85 | 2024-2025 | Cardiomems, Amplatzer Amulet |
| Boston Scientific Corporation | $31.76 | 2024 | Watchman Flx |
| Philips North America LLC | $27.49 | 2025 | Lm Undivided |
| Edwards Lifesciences Corporation | $19.57 | 2019 | |
| Esperion Therapeutics, INC. | $18.76 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.